Leuzy et al. [113] created a parsimonious model, using plasma p-tau217 and tau PET, which was associated with an annual change in the radioligand [18F]RO948 standardized uptake value ratio (SUVR) and could facilitate the recruitment for clinical trials on AD. This evidence concerns the gene MAPT and Alzheimer disease.